Literature DB >> 25452398

Serum free light chains in patients with HIV infection: their association with markers of disease severity and antiretroviral use.

Annalise E Zemlin1, Hayley Ipp2, Megan A Rensburg1, Jurie J Germishuys1, Monika M Esser3, Madeleen Olivier4, Rajiv T Erasmus1.   

Abstract

AIM: Serum free light chain measurements are used to follow-up and manage patients with monoclonal gammopathies, and abnormal ratios are associated with risk of progression in certain diseases. B cell dysfunction is well described in HIV and patients are at risk of developing B cell lymphomas. This study investigated whether HIV is associated with abnormal free light chain levels and the impact of antiretroviral treatment (ART) on these.
METHODS: κ And λ free light chain concentrations and ratios, serum albumin and immunoglobulin G (IgG) were measured in 366 HIV positive subjects and correlated with CD4+ counts, viral loads, IgG, albumin and ART use.
RESULTS: 66% were women and most were black Africans (66%), 26% were of mixed ethnicity and 8% were Caucasian or of unknown or other race. 89% were on ART. κ Free light chain values ranged from 5.59 to 357.0 mg/L (median 19.6 mg/L) and λ free light chain values ranged from 9.28 to 286 mg/L (median 22.3 mg/L). Both correlated positively with viral load and IgG and negatively with CD4+ counts and albumin concentrations. The ratio only correlated with IgG concentrations. Patients on ART had significantly lower free light chain concentrations, but the ratio was not significantly affected.
CONCLUSIONS: This study demonstrated that free light chain concentrations were significantly correlated with markers of HIV disease severity, suggesting ongoing B cell dysfunction despite ART use. Free light chain ratio was not significantly affected. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25452398     DOI: 10.1136/jclinpath-2014-202733

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  4 in total

1.  Excluding myeloma diagnosis using revised thresholds for serum free light chain ratios and M-protein levels.

Authors:  Jennifer L J Heaney; Alex Richter; Stella Bowcock; Guy Pratt; J Anthony Child; Graham Jackson; Gareth Morgan; Ingemar Turesson; Mark T Drayson
Journal:  Haematologica       Date:  2019-08-08       Impact factor: 9.941

2.  E-Selectin and markers of HIV disease severity, inflammation and coagulation in HIV-infected treatment-naïve individuals.

Authors:  Madelein Hoffman; Hayley Ipp; Dineo V Phatlhane; Rajiv T Erasmus; Annalise E Zemlin
Journal:  Afr Health Sci       Date:  2018-12       Impact factor: 0.927

3.  Development and characterization of polyclonal antibody against human kappa light chain in rabbit.

Authors:  Mojgan Esparvarinha; Hamid Nickho; Leili Aghebati-Maleki; Jalal Abdolalizadeh; Hadi Nasiri; Zahra Valedkarimi; Jafar Majidi
Journal:  Vet Res Forum       Date:  2019-09-15       Impact factor: 1.054

Review 4.  Free Light Chains as a Novel Diagnostic Biomarker of Immune System Abnormalities in Multiple Sclerosis and HIV Infection.

Authors:  Monika Gudowska-Sawczuk; Barbara Mroczko
Journal:  Biomed Res Int       Date:  2019-12-09       Impact factor: 3.411

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.